XT
GLUE icon

XTX Topco’s Monte Rosa Therapeutics GLUE Stock Holding History

XTX Topco’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$950K Buy
57,759
+26,634
+86% +$509K 0.02% 1455
2025
Q4 		$488K Sell
31,125
-19,003
-38% -$256K 0.01% 1624
2025
Q3 		$371K Sell
50,128
-4,312
-8% -$22.8K 0.02% 1329
2025
Q2 		$246K Buy
+54,440
New +$243K 0.01% 1564

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

XTX Topco's GLUE Position: Q1 2026 in Review

XTX Topco increased its Monte Rosa Therapeutics (GLUE) stake by 86% in Q1 2026, buying an estimated $509K and bringing the position to 57,759 shares worth $950K. The position accounts for 0.02% of the portfolio, ranked #1455.

XTX Topco first reported a position in GLUE in Q2 2025 and has held it in 4 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • XTX Topco held 57,759 shares of Monte Rosa Therapeutics worth $950K as of Q1 2026.
  • XTX Topco bought 26,634 Monte Rosa Therapeutics shares in Q1 2026, an estimated $509K.
  • Monte Rosa Therapeutics made up 0.02% of XTX Topco's portfolio in Q1 2026, its #1455 holding.
  • XTX Topco first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.